Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.
Authors not listed
Seqirus · 2023
Abstract
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines.
Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV).
The study will have a treatment period (Day 1 to Day 29) and a follow-up period (Day 30 up to Day 181); a subset of 770 subjects will be followed up up to Day 365.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2023). A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older. <em>Seqirus</em>. https://clinicaltrials.gov/study/NCT06015282
Vancouver
Anonymous. A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older. Seqirus. 2023.
BibTeX
@misc{anon2023APhase,
title = {A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.},
author = {Anonymous},
journal = {Seqirus},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
CanSino Biologics Inc. 2020
Open access · US-GOV
A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada
Yikang Biotech (Suzhou) Co., Ltd. 2026
Open access · US-GOV
A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Guangzhou Patronus Biotech Co., Ltd. 2025
Open access · US-GOV
A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
Abbott Biologicals 2009
Open access · US-GOV
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.
Guangzhou Patronus Biotech Co., Ltd. 2024
Open access · US-GOV
A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older
Jiangsu Rec-Biotechnology Co., Ltd. 2022
Open access · US-GOV